PD-L1 expression: An emerging biomarker in non-small cell lung cancer

Annales de pathologie
Julien AdamSylvie Lantuéjoul

Abstract

Therapies targeting immune checkpoints, in particular programmed death 1 (PD-1) and its ligand programmed death ligand 1 (PD-L1), are major new strategies for the treatment of several malignancies including mestatatic non-small cell lung cancer (NSCLC). The identification of predictive biomarkers of response is required, considering efficacy, cost and potential adverse events. Expression of PD-L1 by immunohistochemistry has been associated with higher response rate and overall survival in several clinical trials evaluating anti-PD-1 and anti-PD-L1 monoclonal antibodies. Thus, PD-L1 immunohistochemical companion assays could be required for treatment with some of these therapies in NSCLC. However, heterogeneity in methodologies of PD-L1 assays in terms of primary antibodies and scoring algorithms, and tumor heterogenity for PD-L1 expression are important issues to be considered. More studies are required to compare the different assays, ensure their harmonization and standardization and identify the optimal conditions for testing. PD-L1 expression is likely an imperfect predictive biomarker for patient selection and association with other markers of the tumor immune microenvironment will be probably necessary in the future.

References

Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
May 17, 2013·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Vamsidhar VelchetiKurt A Schalper
Mar 22, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kurt A SchalperDavid L Rimm
Jun 28, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Antoni Ribas, Paul C Tumeh
Nov 20, 2014·The New England Journal of Medicine·Alexandra SnyderTimothy A Chan
Jan 22, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael A PostowJedd D Wolchok
Feb 11, 2015·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Moon-Young KimDoo Hyun Chung
Feb 16, 2015·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·A WangG T Liu
Mar 24, 2015·Future Oncology·Julie R BrahmerEvan J Lipson
Apr 4, 2015·Science·Padmanee Sharma, James P Allison
Apr 11, 2015·Cancer Cell·Suzanne L TopalianDrew M Pardoll
Apr 12, 2015·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Yih-Leong ChangPan-Chyr Yang
Apr 16, 2015·Cancer Cell·Shin Foong NgiowMark J Smyth
Apr 22, 2015·The New England Journal of Medicine·Edward B GaronUNKNOWN KEYNOTE-001 Investigators
May 29, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Keiichi OtaIsamu Okamoto
May 31, 2015·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Wendy A CooperRichard A Scolyer
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Jul 3, 2015·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Keith M KerrUNKNOWN IASLC Pathology Committee
Aug 20, 2015·Journal for Immunotherapy of Cancer·Leila KhojaAnthony M Joshua
Aug 28, 2015·PloS One·Lars Henning SchmidtWolfgang Hartmann
Sep 1, 2015·Applied Immunohistochemistry & Molecular Morphology : AIMM·Therese PhillipsXiaoling Zhang
Sep 9, 2015·Frontiers in Immunology·Isabelle Le MercierRandolph J Noelle
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Jean-Charles SoriaScott Gettinger
© 2022 Meta ULC. All rights reserved